Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02248597 · ClinicalTrials.gov registry record · Phase 2
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT02248597 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 27 participants.
The verdict
NCT02248597, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This pilot clinical trial studies donor stem cell transplant followed by cyclophosphamide in treating patients with hematological diseases. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving cyclophosphamide after the transplant may stop this from happening.
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- DRUG tacrolimus
- PROCEDURE allogeneic hematopoietic stem cell transplantation
- DRUG busulfan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-02-25 |
| Est. Completion | 2023-01-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02248597
The ClinicalTrials.gov registry entry for NCT02248597 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT02248597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02248597 about?
NCT02248597 is a clinical study titled "Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases". This pilot clinical trial studies donor stem cell transplant followed by cyclophosphamide in treating patients with hematological diseases. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and...
What is the current status of trial NCT02248597?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2015-02-25. Estimated completion is 2023-01-18.
What interventions are being tested in trial NCT02248597?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), tacrolimus (DRUG), allogeneic hematopoietic stem cell transplantation (PROCEDURE), busulfan (DRUG).
Who is sponsoring clinical trial NCT02248597?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.